research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-04. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Among them was an email in which Epstein stated that "Trump knew about the girls," though without it being clear that this refers to Epstein's crimes. On November 18, the Epstein Files Transparency Act cleared the House and Senate with overwhelming majorities, requiring the release of all materials relating to the Epstein investigation within 30 days. This would exclude victims' names, as well as material which depicts sexual abuse. The Justice Department may also withhold any materials whose release would "jeapordise an active federal investigation or ongoing prosecution, provided that such withholding is narrowly tailored and temporary". This fact has drawn concern from certain lawmakers, who argue that recently started, ongoing investigations into Bill Clinton and Larry Summers may delay the release of some materials. The Act also requires the executive branch to provide an unredacted "list of all government officials and politically exposed persons" who are included in the material. CNN has expressed scepticism about this aspect of the Act, arguing in an analysis article that "the administration might play games with whatever discretion it has — say, by releasing information that's politically advantageous but withholding other information using the available justifications." Trump has reversed course and now states he favors the release of the material.
=== Miscellaneous === Italian police sought bribery charges in May 2004, against 4,400 doctors and 273 GSK employees. GSK and its predecessor were accused of having spent £152m on physicians, pharmacists and others, giving them cameras, computers, holidays and cash. Doctors were alleged to have received cash based on the number of patients they treated with a cancer drug, topotecan (Hycamtin). The following month prosecutors in Munich accused 70–100 doctors of having accepted bribes from SmithKline Beecham between 1997 and 1999. The inquiry was opened over allegations that the company had given over 4,000 hospital doctors money and free trips. All charges were dismissed by the Verona court in January 2009. In 2006, in the United States GSK settled the largest tax dispute in IRS history, agreeing to pay US$3.1 billion. At issue were Zantac and other products sold in 1989 to 2005. The case revolved around intracompany transfer pricing—determining the share of profit attributable to the US subsidiaries of GSK and subject to tax by the IRS. The UK's Serious Fraud Office (SFO) opened a criminal inquiry in 2014 into GSK's sales practices, using powers granted by the Bribery Act 2010. The SFO said it was collaborating with Chinese authorities to investigate bringing charges in the UK related to GSK's activities in China, Europe and the Middle East. Also as of 2014, the US Department of Justice was investigating GSK with reference to the Foreign Corrupt Practices Act.
=== Pharmaceutical applications === One major area where automated synthesis has been applied is structure determination in pharmaceutical research. Processes such as NMR and HPLC-MS can now have sample preparation done by robotic arm. Additionally, structural protein analysis can be done automatically using a combination of NMR and X-ray crystallography. Crystallization often takes hundreds to thousands of experiments to create a protein crystal suitable for X-ray crystallography. An automated micropipette machine can allow nearly a million different crystals to be created at once, and analyzed via X-ray crystallography.
Sources: en.wikipedia.org
== Manifestations of chirality == Flavor: the artificial sweetener aspartame has two enantiomers. L-aspartame tastes sweet whereas D-aspartame is tasteless. Odor: R-(–)-carvone smells like spearmint whereas S-(+)-carvone smells like caraway. Drug effectiveness: the antidepressant drug citalopram is sold as a racemic mixture. However, studies have shown that only the (S)-(+) enantiomer (escitalopram) is responsible for the drug's beneficial effects. Drug safety: D‑penicillamine is used in chelation therapy and for the treatment of rheumatoid arthritis whereas L‑penicillamine is toxic as it inhibits the action of pyridoxine, an essential B vitamin.
=== Proposed re-engined versions === In the 1980s, there were moves to fit the Il-86 with RB211-22 engines. Designated Il-86V (second use of this designation), this would have had a range of over 9,000 km (4,860 nmi) and/or increased payload. Another 450-seater Il-86V powered by RB211-524G engines was also projected. Amid the disintegration of the Soviet economy, these versions did not progress. In 1991, there were moves to fit the Il-86 with Franco-American CFM56-5C2 engines. Finances precluded progress. In 1995, International Aero Engines offered the V2500 engine to five Il-86 operators with proposals to re-engine 25 aircraft. The offer was not taken up.
Finally, Marshall and coworkers found that P-selectin:PSGL-1 bonds exhibited increasing bond lifetime as step loads were applied between 0 and ~10 pN for monomeric interaction but 1 and ~20 pN for dimeric interaction, exhibiting catch bond behavior; after reaching maximum values, which were ~0.6 and 1.2 seconds for monomeric and dimeric interaction, respectively, the bond lifetime fell rapidly at higher loads, displaying slip bond behavior ("catch-slip" bonds). These data were collected using an atomic force microscope and a flow chamber, and have subsequently been duplicated using a biomembrane force probe. These finding prompted the discoveries of other important catch bonds in the 2000s, including those between L-selectin and PSGL-1 or endoglycan, FimH and mannose, myosin and actin, platelet glycoprotein Ib and von Willebrand factor, and integrin alpha 5 beta 1 and fibronectin. Emphasizing their importance and general acceptance, in the three years following their discovery there were at least 24 articles published on catch bonds. More catch bonds were discovered in the 2010s, including E-selectin with carbohydrate ligands, G-actin with G-actin or F-actin, cadherin-catenin complex with actin, vinculin with F-actin, microtubule with kinetochore particle, integrin alpha L beta 2 and intercellular adhesion molecule 1 (ICAM-1), integrin alpha 4 beta 1 with vascular adhesion molecule 1, integrin alpha M beta 2 with ICAM-1, integrin alpha V beta 3 with fibronectin, and integrin alpha IIb beta 3 with fibronectin or fibrinogen.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.